Paula Goodman Fraenkel, MD, is a physician-scientist specializing in Hematology and Medical Oncology. She is Executive Director, Global Project and Oncology Lead at AstraZeneca, and serves as a Tutor in Biochemical Sciences at Harvard University. She is also an affiliated physician with Beth Israel Deaconess Medical Center. Her clinical work centers on oncology therapeutics development, nonmalignant hematology with an emphasis on iron biology and anemia syndromes, and the care of patients with hematologic cancers. Her research interests include iron metabolism and hepcidin regulation, translational oncology drug development, and biomarker-driven clinical trial design in immuno-oncology. Dr. Fraenkel is a recipient of an ASH Scholar Award and holds leadership roles spanning global oncology clinical development and academic mentorship at Harvard. She earned her MD from Harvard Medical School, completed an Internal Medicine residency at New England Medical Center (now Tufts Medical Center), and completed fellowship training in Hematology and Oncology at Beth Israel Deaconess Medical Center.
Global Clinical Program Lead
Medical School
1991 – 1995
Residency
1995 – 1998
Fellowship
1998 – 2002